Akimoto S, Masai M, Akakura K, Shimazaki J
Department of Urology, School of Medicine, Chiba University, Japan.
Eur Urol. 1995;27(3):207-12. doi: 10.1159/000475162.
To estimate the growth rate of prostate cancer, the doubling times of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) were determined in 51 patients: 44 were refractory to endocrine therapy, and 7 were in an untreated state. Since an exponential increase in PSA and PAP was observed in all patients, the doubling time was calculated from a semilogarithmic plot of the respective markers. PSA doubling time was almost identical with that of PAP. The tumor marker doubling time in untreated patients was approximately 10 times greater than that in the patients who were refractory to endocrine therapy. In endocrine refractory patients, the tumor marker doubling time in patients who showed deterioration of bone lesions was less than that in patients with local regrowth and/or lymph node metastasis. The prognosis of endocrine refractory patients from the time showing tumor marker failure was examined. The group showing the longest time (> 80 days) had better prognosis than that shown by the other groups with shorter doubling times. It is concluded that the determination of tumor marker doubling time is of value for measuring the growth rates of prostate cancer, and for assessing prognosis after relapse.
为评估前列腺癌的生长速率，测定了51例患者前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）的倍增时间：44例对内分泌治疗无效，7例处于未治疗状态。由于在所有患者中均观察到PSA和PAP呈指数增长，因此从各标志物的半对数图计算倍增时间。PSA倍增时间与PAP几乎相同。未治疗患者的肿瘤标志物倍增时间约为对内分泌治疗无效患者的10倍。在内分泌抵抗患者中，骨病变恶化患者的肿瘤标志物倍增时间短于局部复发和/或淋巴结转移患者。研究了内分泌抵抗患者自出现肿瘤标志物失效起的预后情况。倍增时间最长（>80天）的组比其他倍增时间较短的组预后更好。结论是，测定肿瘤标志物倍增时间对于衡量前列腺癌的生长速率以及评估复发后的预后具有价值。
